(VIANEWS) – The NYSE ended the session with Fresenius Medical Care AG (FMS) rising 11.38% to $20.80 on Tuesday while NYSE dropped 0.49% to $17,662.19.
Fresenius Medical Care AG’s last close was $18.67, 32.65% below its 52-week high of $27.72.
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Earnings Per Share
As for profitability, Fresenius Medical Care AG has a trailing twelve months EPS of $0.88.
PE Ratio
Fresenius Medical Care AG has a trailing twelve months price to earnings ratio of 23.63. Meaning, the purchaser of the share is investing $23.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.84%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Fresenius Medical Care AG’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 19.45B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 31.9% and positive 27.6% for the next.
More news about Fresenius Medical Care AG (FMS).
